Provided by Tiger Trade Technology Pte. Ltd.

Entrada Therapeutics, Inc.

7.33
-0.2400-3.17%
Post-market: 7.330.00000.00%19:30 EDT
Volume:184.25K
Turnover:1.35M
Market Cap:284.56M
PE:-1.85
High:7.58
Open:7.58
Low:7.12
Close:7.57
52wk High:16.45
52wk Low:5.02
Shares:38.82M
Float Shares:26.88M
Volume Ratio:0.96
T/O Rate:0.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9676
EPS(LYR):-3.4746
ROE:-54.09%
ROA:-29.20%
PB:1.22
PE(LYR):-2.11

Loading ...

Guggenheim Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)

TIPRANKS
·
Apr 24

Entrada publishes corporate deck outlining DMD, DM1 pipeline catalysts and $5 billion US market opportunity

Reuters
·
Apr 07

Entrada Therapeutics Q2 Data Could Drive Platform Differentiation, Oppenheimer Says

MT Newswires Live
·
Apr 07

Entrada Therapeutics Is Maintained at Outperform by Oppenheimer

Dow Jones
·
Apr 06

Oppenheimer Adjusts Price Target on Entrada Therapeutics to $23 From $21, Maintains Outperform Rating

MT Newswires Live
·
Apr 06

Entrada Therapeutics, Inc. : Oppenheimer Raises Target Price to $23 From $21

THOMSON REUTERS
·
Apr 06

U.S. RESEARCH ROUNDUP-EQT, Las Vegas Sands, Twilio

Reuters
·
Apr 06

Entrada CFO Kory James Wentworth sells $0 million Entrada Therapeutics common shares

Reuters
·
Apr 03

Cantor Fitzgerald Initiates Coverage on Entrada Therapeutics With Overweight Rating

MT Newswires Live
·
Apr 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA), Apellis Pharmaceuticals (APLS) and MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Apr 01

Entrada Therapeutics CFO Kory James Wentworth Disposes of Common Shares

Reuters
·
Mar 12

Entrada Therapeutics CFO Kory James Wentworth Disposes of Common Shares

Reuters
·
Mar 07

Entrada Therapeutics Publishes Corporate Presentation on DMD, DM1 and Inherited Retinal Disease Pipeline

Reuters
·
Mar 03

Entrada Therapeutics Grants 12,990 RSUs to Newly Hired Employees Under 2025 Inducement Plan

Reuters
·
Mar 03

Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics

TIPRANKS
·
Mar 02

Entrada Therapeutics Inc (TRDA) Gets a Buy from Roth MKM

TIPRANKS
·
Feb 27

Entrada Therapeutics Publishes Corporate Presentation on Genetic Medicines Pipeline for DMD, DM1 and Inherited Retinal Diseases

Reuters
·
Feb 26

Entrada Therapeutics Q4 net loss and EPS beat expectations

Reuters
·
Feb 26

Entrada Therapeutics Q4 EPS $(0.94) Beats $(1.07) Estimate, Sales $1.299M Miss $13.886M Estimate

Benzinga Earnings
·
Feb 26

Entrada Therapeutics, Inc. Q4 Collaboration Revenue USD 1.299 Million

THOMSON REUTERS
·
Feb 26